Regeneron Bispecific Approved for Myeloma; Concentra to Buy IGM

Regeneron bispecific approved for myeloma; Concentra to buy IGM

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Kevin Tang's Concentra snags another buyout, this time for IGM Biosciences

Kevin Tang is on a hot streak. Concentra Biosciences, the shell company from his hedge fund Tang Capital, has secured its fourth buyout of a struggling biotech so far in 2025. This time, Concentra is ...